Day 1 - Industry Summit - 10 February

09:00
  • Looking into how cannabinoids are being used across sector i.e. cosmetics, beverages and more
  • Insights into evidence on consumption trends across the globe
    • What impact is medicinal cannabis having?
  • How is this driving product design in the industry?

Melissa Clark-Reynolds Futurist, futurecentre.nz
09:50
  • Comparing New Zealand’s medicinal cannabis industry to the world
  • The opportunity to join the global industry and be amongst the global players
  • What is unique about New Zealand’s harvest (and product) to drive a global opportunity to drive our economy as well as contribute to global healthcare and wellbeing outcomes?
  • What are the milestones that the industry needs to reach to achieve a commercially sustainable industry?
  • Keeping it local – what are the collaboration options for Maori businesses and organisations to expand their interest in primary industries?
Carmen Doran Chief Executive Officer, Helius Therapeutics
Rob Mitchell Chief Executive Officer, Rua Bioscience
Mark Lucas Chief Executive Officer, Cannasouth
Tim Aldridge Managing Director, Puro
Mitch Cuevas Pharmaceutical Director, Eqalis
10:30
  • Medicinal cannabis licensing regime
  • Verification of products against the minimum quality standards
  • Regulation changes
Andrea Eng Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
11:30
11:30
Industry
Carmen Doran Chief Executive Officer, Helius Therapeutics
Eva Neshat Founder and Chief Executive Officer, Elysian Pharmaceuticals & CannaCare Clinic
Zoë Reece Founder and CEO, Ora Pharm
12:00
Industry

This panel showcases some key players in New Zealand’s primary industries and how they are harnessing their brand story and aligning it with New Zealand’s story. This panel will shed light on the value chain opportunity and how medicinal cannabis can follow suit.
● Using New Zealand’s clean green image, in the local medicinal cannabis industry – how can we leverage this for our value chain?
● Coming together and collaborating to advocate for the industry – what is the opportunity here?

12:30
Industry

This presentation will highlight the commercial potential for medicinal cannabis or hemp beyond its primary use by taking a ‘whole of resource’ approach. It will outline how the Bioresource Processing Alliance and research providers can help industry partners identify high-value opportunities from low-value biological resources.

Andrew Cameron Principal Consultant, Callaghan Innovation
Anna Yallop General Manager, Bioresource Processing Alliance
14:00
Industry
  • A glimpse into the journey of bringing a product in the market
  • The challenges and barriers faced in making this a reality
  • Specific challenges tackling different regulatory systems around the world
  • Breaking barriers in product to market strategies – what are the learnings?
  • The way forward

Peter Crock Chief Executive Officer, Cann Group
15:00
Industry

• Types of investment
• Trends
• Future of investments

Kristen Lunman Co-Founder and GM, Hatch
16:00
  • The journey of medicinal cannabis – from seed to shelf – why this is and should be considered a medicine 
  • Working with the industry to educate on the benefits of medicinal cannabis 
  • Showcasing the evidence of the impact of medicinal cannabis in treating sickness
  • Combatting the misconception of addiction of medicinal cannabis in usage for treatment 
Dr Dave Hepburn Medical Advisor, CloudForest Peru
16:40
  • Providing an overview of AUS/NZ approach to growing cannabis for medicinal purposes
    • An in-depth discussion on indoor versus outdoor growth – how do they differ and will one dominate over the other?
  • Showcasing technology in play to capture data and assisting with cultivation
  • The road that lays ahead – opportunities for growth and collaboration
Tom Forrest Cultivation Director, Puro
09:00
  • Looking into how cannabinoids are being used across sector i.e. cosmetics, beverages and more
  • Insights into evidence on consumption trends across the globe
    • What impact is medicinal cannabis having?
  • How is this driving product design in the industry?

Melissa Clark-Reynolds Futurist, futurecentre.nz
09:50
  • Comparing New Zealand’s medicinal cannabis industry to the world
  • The opportunity to join the global industry and be amongst the global players
  • What is unique about New Zealand’s harvest (and product) to drive a global opportunity to drive our economy as well as contribute to global healthcare and wellbeing outcomes?
  • What are the milestones that the industry needs to reach to achieve a commercially sustainable industry?
  • Keeping it local – what are the collaboration options for Maori businesses and organisations to expand their interest in primary industries?
Carmen Doran Chief Executive Officer, Helius Therapeutics
Rob Mitchell Chief Executive Officer, Rua Bioscience
Mark Lucas Chief Executive Officer, Cannasouth
Tim Aldridge Managing Director, Puro
Mitch Cuevas Pharmaceutical Director, Eqalis
10:30
  • Medicinal cannabis licensing regime
  • Verification of products against the minimum quality standards
  • Regulation changes
Andrea Eng Manager of Regulatory Practice & Analysis, Medicinal Cannabis Agency, Ministry of Health
11:30
Imche Fourie Co-Founder & CEO, Outset Ventures
11:30
Science
Associate Professor Jonathan Arnold Deputy Academic Director, Sydney Pharmacy School Lambert Initiative for Cannabinoid Therapeutics
12:00
Science

• New Zealand gene bank
• different genetic technologies
• development of unique plants to those grown internationally
• Which traits to select- from disease resistance to cannabinoid profiles
• role of data management in a well-run breeding programme

Dr Anna Campbell Consultant, AbacusBio
14:00
Science
  • Highlighting the different services available in cannabis testing in New Zealand
    • How does New Zealand rank globally on testing?
  • Providing a global view – what are the trends we are seeing in cannabis testing around the world?
  • Any key learnings for New Zealand to implement?

 

14:30
Science
  • Making the business case for commercialising medicinal cannabis whilst adhering to the regulations – how can this be achieved effectively?
  •  Understanding methodological innovations required when undertaking Research on cannabis

Dr. Adele Hosseini, PhD Chief Scientific Officer, Bod Australia
15:00
Science
Dr Rachel Galettis Clinical Trial Manager, Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE)
16:00
  • The journey of medicinal cannabis – from seed to shelf – why this is and should be considered a medicine 
  • Working with the industry to educate on the benefits of medicinal cannabis 
  • Showcasing the evidence of the impact of medicinal cannabis in treating sickness
  • Combatting the misconception of addiction of medicinal cannabis in usage for treatment 
Dr Dave Hepburn Medical Advisor, CloudForest Peru
16:40
  • Providing an overview of AUS/NZ approach to growing cannabis for medicinal purposes
    • An in-depth discussion on indoor versus outdoor growth – how do they differ and will one dominate over the other?
  • Showcasing technology in play to capture data and assisting with cultivation
  • The road that lays ahead – opportunities for growth and collaboration
Tom Forrest Cultivation Director, Puro